<DOC>
	<DOCNO>NCT00949013</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict patient enrol clinical trial SWOG-9313 respond doxorubicin cyclophosphamide . PURPOSE : This laboratory study look tumor tissue sample woman early-stage breast cancer enrol clinical trial SWOG-9313 .</brief_summary>
	<brief_title>S9313B Study Tumor Tissue Samples From Women With Early-Stage Breast Cancer Enrolled Clinical Trial SWOG-9313</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine ALDH1 positivity , determine IHC staining , identifies poor prognostic subgroup woman early-stage breast cancer uniformly treat adjuvant doxorubicin cyclophosphamide clinical trial SWOG-9313 . Secondary - To determine association ALDH1 expression know factor determine clinical trial SWOG-9313 , estrogen receptor ( ER ) status , HER2 status , TOPOII , cyclin E , p27 . - To determine ALDH1 positivity , determine IHC staining , identifies poor prognostic subgroup within ER HER2 subgroups patient treated clinical trial SWOG-9313 . OUTLINE : This multicenter study . Tumor tissue sample clinical trial SWOG-9313 analyze ALDH1 expression IHC .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Tumor sample collect woman diagnose earlystage breast cancer clinical trial SWOG9313 available PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>